NNVC - NanoViricides, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc.

NNVC 1.160

+2.7%

Jan 16 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Straynut who wrote (10043)	4/9/2018 8:09:13 AM
From: old 'n cranky	Read Replies (1) of 12873

"These drug candidates will now advance towards the full battery of GLP safety and toxicology studies that are needed for filing an Investigational New Drug (IND) application with the US FDA, prior to beginning human clinical trials." Sounds good, but still plural "candidates" and "now advance toward" GLP safety and toxicology? Will those things be changing at some point? In other words is there a goal to have a single candidate going into GLP safety and toxicology and what is standing between now advancing and actually starting? Will any further efficacy testing be done to distinguish between the candidates between now and GLP safety and toxicology? Or is it the ultimate intent to secure the approval of multiple drugs to treat the individual "alphaherpesviruses"? If the answer requires the use of the term "broad spectrum" I hope it includes a further explanation.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next